{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-003346","form_type":"8-K","ticker":null,"cik":"0000793171","company_name":"Vitro Biopharma, Inc.","filed_at":"2024-01-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.935967+00:00","generated_at":"2026-06-06T20:21:16.696312+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Vitro Biopharma appoints Thomas Ohrt as CFO; former CFO Nathan Haas to consult","bullets":["Nathan Haas resigned as CFO effective Jan 18, 2024; entered into Settlement and Consulting Agreements.","Haas to receive $175k unpaid bonus upon qualified financing or direct listing; 2023 bonus by April 1, 2024.","Haas will serve as strategy consultant for four months at $15,000/month.","Thomas Ohrt appointed CFO, salary $250k/year, eligible for $125k target performance bonus.","Ohrt served as controller since Jan 2021; 35 years of financial leadership experience."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-003346","json":"https://secwatch.observer/filing/0001493152-24-003346.json","markdown":"https://secwatch.observer/filing/0001493152-24-003346.md","text":"https://secwatch.observer/filing/0001493152-24-003346.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/793171/000149315224003346/0001493152-24-003346-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/793171/000149315224003346/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T20:21:16.696312+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8d5385ee2d","claim":"Nathan Haas resigned as Chief Financial Officer at Vitro Biopharma, Inc..","evidence_excerpt":"Pursuant to the Settlement Agreement, the parties confirmed Mr. Haas’s resignation as Chief Financial Officer, effective January 18, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/793171/000149315224003346/0001493152-24-003346-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"f77694abd4","claim":"Thomas W. Ohrt was appointed as Chief Financial Officer at Vitro Biopharma, Inc..","evidence_excerpt":"On January 22, 2024, Thomas W. Ohrt was appointed the Company’s Chief Financial Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/793171/000149315224003346/0001493152-24-003346-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}